Rozlytrek (Entrectinib) for Ovarian Cancer | MyOvarianCancerTeam

Connect with others who understand.

sign up Log in
About MyOvarianCancerTeam
Powered By

Rozlytrek is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat cancerous tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known resistance mutation, are metastatic or for which surgical removal is too risky, and that grew following treatment or have no satisfactory alternative therapy. Rozlytrek is sometimes prescribed to treat ovarian cancer. Rozlytrek is also referred to by its drug name, entrectinib.

Rozlytrek is a member of a class of drugs called tyrosine kinase inhibitors. Rozlytrek is believed to work by disrupting the activity of ROS1 and several other kinases involved in the proliferation of tumors. Inhibiting these kinases slows cancer cell replication and triggers cell death.

How do I take it?
Prescribing information states that Rozlytrek is taken orally as a capsule once daily.

Rozlytrek should be taken exactly as prescribed by a physician.

Side effects
The FDA-approved label for Rozlytrek lists common side effects including fatigue, constipation, altered taste sensation, edema (swelling), dizziness, diarrhea, nausea, numbness and tingling of the skin, shortness of breath, muscle pain, cognitive impairment, weight gain, cough, vomiting, fever, and joint pain.

Rare but serious side effects listed for Rozlytrek include congestive heart failure, mood disorders, bone fractures, liver damage, abnormal heart rhythms, vision disorders, and fetal harm.

For more details about this treatment, visit:

Rozlytrek — Genentech

Entrectinib — (Oral Route)

Continue with Facebook
Continue with Google
Lock Icon Your privacy is our priority. By continuing, you accept our Terms of use, and our Health Data and Privacy policies.
Already a Member? Log in